Diagnosis and treatment of narcotic bowel syndrome

Nature Reviews Gastroenterology and Hepatology

Volumn 11, Issue 7, 2014, Pages 410-418

  Kurlander, Jacob E ^a   Drossman, Douglas A ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXANTRAZOLE; G PROTEIN COUPLED RECEPTOR; MINOCYCLINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; OPIATE; OPIATE AGONIST; OPIATE ANTAGONIST; OPIATE RECEPTOR; TOLL LIKE RECEPTOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; CELL ACTIVATION; CLINICAL FEATURE; COMORBIDITY; DIFFERENTIAL DIAGNOSIS; DOCTOR PATIENT RELATION; DRUG DETOXIFICATION; DRUG TREATMENT FAILURE; GLIA CELL; HUMAN; MENTAL DISEASE; MOLECULAR PATHOLOGY; NARCOTIC BOWEL SYNDROME; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SUBSTANCE ABUSE; TREATMENT PLANNING;

HUMANS; INTESTINAL DISEASES; NARCOTICS;

EID: 84903815373     PISSN: 17595045     EISSN: 17595053     Source Type: Journal    
DOI: 10.1038/nrgastro.2014.53     Document Type: Review

References (87)

1. Mularski, R. A. et al. Measuring pain as the 5th vital sign does not improve quality of pain management. J. Gen. Intern. Med. 21, 607-612 (2006). (Pubitemid 43801490)
2. Berry, P. H. & Dahl, J. H. Making pain assessment and management a healthcare system priority through the new JCAHO pain standards. J. Pharm. Care Pain Symptom Control 8, 5-20 (2000). (Pubitemid 30663986)
3. Kenan, K., Mack, K. & Paulozzi, L. Trends in prescriptions for oxycodone and other commonly used opioids in the United States, 2000-2010. Open Med. 6, e41 (2012).
4. Ballantyne, J. C. & Mao, J. Opioid therapy for chronic pain. N. Engl. J. Med. 349, 1943-1953 (2003). (Pubitemid 37409712)
5. Dorn, S. D., Meek, P. D. & Shah, N. D. Increasing frequency of opioid prescriptions for chronic abdominal pain in US outpatient clinics. Clin. Gastroenterol. Hepatol. 9, 1078-1085 (2011).
6. Maxwell, J. C. The prescription drug epidemic in the United States: a perfect storm. Drug Alcohol Rev. 30, 264-270 (2011).
7. Sandgren, J., McPhee, M. & Greenberger, N. Narcotic bowel syndrome treated with clonidine. Resolution of abdominal pain and intestinal pseudo-obstruction. Ann. Intern. Med. 101, 331-334 (1984). (Pubitemid 14033780)
8. Grunkemeier, D., Cassara, J., Dalton, C. & Drossman, D. The narcotic bowel syndrome: clinical features, pathophysiology, and management. Clin. Gastroenterol. Hepatol. 5, 1126-1239 (2007).
9. Agostini, S. et al. Evidence of central and peripheral sensitization in a rat model of narcotic bowel-like syndrome. Gastroenterology 139, 553-563 (2010).
10. Chu, L., Angst, M. & Clark, D. Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. J. Pain 24, 479-496 (2008).
11. Low, Y., Clarke, C. & Huh, B. Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med. J. 53, 357-360 (2012).
12. Lee, M., Silverman, S., Hansen, H., Patel, V. & Manchikanti, L. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14, 145-161 (2011).
13. Grover, C. A., Wiele, E. D. & Close, R. J. Narcotic bowel syndrome. J. Emerg. Med. 43, 992-995 (2012).
14. Farmer, A. D., Ferdinand, E. & Aziz, Q. Opioids and the gastrointestinal tract-A case of narcotic bowel syndrome and literature review. J. Neurogastroenterol. Motil. 19, 94-98 (2013).
15. Gibson, P. R. & Morrison, G. Effects of methylnaltrexone in patients with narcotic bowel syndrome: a pilot observational study. Intern. Med. J. 42, 907-912 (2012).
16. Wong, V., Sobala, G. & Losowsky, M. A case of narcotic bowel syndrome successfully treated with clonidine. Postgrad. Med. J. 70, 138-140 (1994). (Pubitemid 24074639)
17. Bruera, E., Brenneis, C., Michaud, M. & MacDonald, N. Continuous Sc infusion of metoclopramide for treatment of narcotic bowel syndrome. Cancer Treat. Rep. 71, 1121-1122 (1987). (Pubitemid 18002237)
18. Drossman, D. A. et al. Diagnosis, characterization, and 3-month outcome after detoxification of 39 patients with narcotic bowel syndrome. Am. J. Gastroenterol. 107, 1426-1440 (2012).
19. Rogers, M. & Cerda, J. The narcotic bowel syndrome. J. Clin. Gastroenterol. 11, 132-135 (1989). (Pubitemid 19104431)
20. Rosti, G., Gatti, A., Costantini, A., Sabato, A. & Zucco, F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur. Rev. Med. Pharmacol. Sci. 14, 1045-1050 (2010).
21. Bell, T. J. et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European patient survey (PROBE 1). Pain Med. 10, 35-42 (2009).
22. Panchal, S. J., Müller-Schwefe, P. & Wurzelmann, J. I. Opioid-induced bowel dysfunction: prevalence, pathophysiology and burden: opioid-induced bowel dysfunction. Int. J. Clin. Pract. 61, 1181-1187 (2007). (Pubitemid 46934629)
23. De Schepper, H. U., Cremonini, F., Park, M.-I. & Camilleri, M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol. Motil. 16, 383-394 (2004). (Pubitemid 39140632)
24. Tuteja, A. K., Biskupiak, J., Stoddard, G. J. & Lipman, A. G. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Neurogastroenterol. Motil. 22, 424-e96 (2010).
25. Choung, R. S., Locke, G. R., Zinsmeister, A. R., Schleck, C. D. & Talley, N. J. Opioid bowel dysfunction and narcotic bowel syndrome: a population-based study. Am. J. Gastroenterol. 104, 1199-1204 (2009).
26. Grover, M., Herfarth, H. & Drossman, D. A. The functional-organic dichotomy: postinfectious irritable bowel syndrome and inflammatory bowel disease-irritable bowel syndrome. Clin. Gastroenterol. Hepatol. 7, 48-53 (2009).
27. Drossman, D. A. Presidential address: gastrointestinal illness and the biopsychosocial model. Psychosom. Med. 60, 258-267 (1998). (Pubitemid 28279969)
28. Drossman, D. A. Functional versus organic: an inappropriate dichotomy for clinical care. Am. J. Gastroenterol. 101, 1172-1175 (2006). (Pubitemid 43829976)
29. Ballantyne, J. C. & LaForge, K. S. Opioid dependence and addiction during opioid treatment of chronic pain. Pain 129, 235-255 (2007). (Pubitemid 46754581)
30. Chang, G., Chen, L. & Mao, J. Opioid tolerance and hyperalgesia. Med. Clin. North Am. 91, 199-211 (2007).
31. American Psychiatric Association, American Psychiatric Association & DSM-5 Task Force. Diagnostic and statistical manual of mental disorders: DSM-5. (American Psychiatric Association, 2013).
32. American Psychiatric Association, American Psychiatric Association & Task Force on DSM-IV. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. (American Psychiatric Association, 2000).
33. Savage, S. et al. Definitions related to the medical use of opioids: evoluation towards universal agreement. J. Pain Symptom Manage. 26, 655-667 (2003). (Pubitemid 36802289)
34. McLellan, A. T., Lewis, D. C., O'Brien, C. P. & Kleber, H. D. Drug dependence, a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 284, 1689-1695 (2000).
35. Miotto, K., Compton, P., Ling, W. & Conolly, M. Diagnosing addictive disease in chronic pain patients. Psychosomatics 37, 223-235 (1996). (Pubitemid 26131984)
36. Højsted, J., Nielsen, P. R., Guldstrand, S. K., Frich, L. & Sjøgren, P. Classification and identification of opioid addiction in chronic pain patients. Eur. J. Pain 14, 1014-1020 (2010).
37. Savage, S. What to do when pain and addiction coexist. J. Fam. Pract. 62 (Suppl. 6), S10-S16 (2013).
38. Woolf, C. J. & Salter, M. W. Neuronal plasticity: increasing the gain in pain. Science 288, 1765-1768 (2000). (Pubitemid 30399008)
39. Cao, H. & Zhang, Y.-Q. Spinal glial activation contributes to pathological pain states. Neurosci. Biobehav. Rev. 32, 972-983 (2008).
40. Ferrini, F. et al. Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl- homeostasis. Nat. Neurosci. 16, 183-192 (2013).
41. Chiang, C.-Y., Sessle, B. J. & Dostrovsky, J. O. Role of astrocytes in pain. Neurochem. Res. 37, 2419-2431 (2012).
42. Watkins, L. R., Milligan, E. D. & Maier, S. F. Glial activation: a driving force for pathological pain. Trends Neurosci. 24, 450-455 (2001). (Pubitemid 32695356)
43. Wang, X. et al. Morphine activates neuroinflammation in a manner parallel to endotoxin. Proc. Natl Acad. Sci. USA 109, 6325-6330 (2012).
44. Hutchinson, M. R. et al. Opioid-induced glial activation: mechanisms of activation and implications for opioid analgesia, dependence, and reward. Sci. World J. 7, 98-111 (2007). (Pubitemid 350292608)
45. Song, P. & Zhao, Z.-Q. The involvement of glial cells in the development of morphine tolerance. Neurosci. Res. 39, 281-286 (2001). (Pubitemid 32186379)
46. Hutchinson, M. R. et al. Exploring the neuroimmunopharmacology of opioids: an integrative review of mechanisms of central immune signaling and their implications for opioid analgesia. Pharmacol. Rev. 63, 772-810 (2011).
47. Hutchinson, M. R. et al. Evidence that tricyclic small molecules may possess Toll-like receptor and myeloid differentiation protein 2 activity. Neuroscience 168, 551-563 (2010).
48. Li, F. & Tsien, J. Z. Memory and the NMDA receptors. N. Engl. J. Med. 361, 302-303 (2009).
49. Mao, J. Opioid-induced abnormal pain sensitivity: implications in clinical opioid therapy. Pain 100, 213-217 (2002). (Pubitemid 35449233)
50. Silverman, S. M. Opioid induced hyperalgesia: Clinical implications for the pain practitioner. Pain Physician 12, 679-684 (2009).
51. Ossipov, M. H., Lai, J., King, T., Vanderah, T. W. & Porreca, F. Underlying mechanisms of pronociceptive consequences of prolonged morphine exposure. Pept. Sci. 80, 319-324 (2005). (Pubitemid 40791062)
52. Célèrier, E., Laulin, J.-P., Corcuff, J.-B., Le Moal, M. & Simonnet, G. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration: a sensitization process. J. Neurosci. 21, 4074-4080 (2001). (Pubitemid 32466499)
53. Crain, S. M. & Shen, K.-F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol. Sci. 11, 77-81 (1990). (Pubitemid 20041666)
54. Crain, S. M. & Shen, K.-F. Antagonists of excitatory opioid receptor functions enhance morphine's analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84, 121-131 (2000). (Pubitemid 30074213)
55. Gan, T. J. et al. Opioid-sparing effects of a low-dose infusion of naloxone in patient-administered morphine sulfate. Anesthesiology 87, 1075-1081 (1997). (Pubitemid 27469306)
56. Gebhart, G. F. Descending modulation of pain. Neurosci. Biobehav. Rev. 27, 729-737 (2004). (Pubitemid 38199605)
57. Vanderah, T. W. et al. Tonic descending facilitation from the rostral ventromedial medulla mediates opioid-induced abnormal pain and antinociceptive tolerance. J. Neurosci. 21, 279-286 (2001). (Pubitemid 32098751)
58. Porreca, F., Ossipov, M. H. & Gebhart, G. F. Chronic pain and medullary descending facilitation. Trends Neurosci. 25, 319-325 (2002). (Pubitemid 34667014)
59. Gardell, L. R. et al. Sustained morphine exposure induces a spinal dynorphin-dependent enhancement of excitatory transmitter release from primary afferent fibers. J. Neurosci. 22, 6747-6755 (2002). (Pubitemid 35386431)
60. Vanderah, T. W. et al. Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance. J. Neurosci. 20, 7074-7079 (2000).
61. Mao, J., Price, D. D. & Mayer, D. J. Mechanisms of hyperalgesian and morphine tolerance: a current view of their possible interactions. Pain 62, 259-274 (1995).
62. Davis, M. P. Drug management of visceral pain: Concepts from basic research. Pain Res. Treat. (2012).
63. Anand, P., Aziz, Q., Willert, R. & Van Oudenhove, L. Peripheral and central mechanisms of visceral sensitization in man. Neurogastroenterol. Motil. 19, 29-46 (2007). (Pubitemid 46058981)
64. Sarkar, S., Aziz, Q., Woolf, C. J., Hobson, A. R. & Thompson, D. G. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 356, 1154-1159 (2000).
65. Lian, B., Vera-Portocarrero, L., King, T., Ossipov, M. H. & Porreca, F. Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity. Brain Res. 1358, 64-70 (2010).
66. Drossman, D. A. 2012 David Sun Lecture: Helping your patient by helping yourself-how to improve the patient-physician relationship by optimizing communication skills. Am. J. Gastroenterol. 18, 521-528 (2013).
67. Adams, J. A balancing act. Ann. Intern. Med. 157, 215-216 (2012).
68. Matthias, M. S. et al. The patient-provider relationship in chronic pain care: providers' perspectives. Pain Med. 11, 1688-1697 (2010).
69. Braddock, C. H. 3rd & Snyder, L. The doctor will see you shortly. The ethical significance of time for the patient-physician relationship. J. Gen. Intern. Med. 20, 1057-1062 (2005). (Pubitemid 41726663)
70. Drossman, D. A. Psychosocial sound bites: Exercises in the patient-doctor relationship. Am. J. Gastroenterol. 92, 1418-1423 (1997). (Pubitemid 27412858)
71. Frantsve, L. M. E. & Kerns, R. D. Patient-provider interactions in the management of chronic pain: current findings within the context of shared medical decision making. Pain Med. 8, 25-35 (2007). (Pubitemid 46128764)
72. Chang, L. & Drossman, D. A. Optimizing patient care: The psychosocial interview in irritable bowel syndrome. Clin. Perspect. Gastroenterol. 5, 336-342 (2002). (Pubitemid 36008280)
73. Platt, D. F. W. & Keller, V. F. Empathic communication. J. Gen. Intern. Med. 9, 222-226 (1994).
74. Coulehan, J. L. et al. 'Let me see if I have this right ': words that help build empathy. Ann. Intern. Med. 135, 221-227 (2001). (Pubitemid 32738320)
75. Dekel, R., Drossman, D. & Sperber, A. The use of psychotropic drugs in irritable bowel syndrome. Expert Opin. Investig. Drugs 22, 329-339 (2013).
76. Gossop, M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Depend. 21, 253-259 (1988).
77. Butler, S. F., Budman, S. H., Fanciullo, G. J. & Jamison, R. N. Cross validation of the Current Opioid Misuse Measure (COMM) to monitor chronic pain patients on opioid therapy. Clin. J. Pain 26, 770 (2010).
78. Butler, S. F. et al. Development and validation of the current opioid misuse measure. Pain 130, 144-156 (2007). (Pubitemid 46843461)
79. Siniscalchi, A. et al. Opioid-induced hyperalgesia and rapid opioid detoxification after tacrolimus administration. Anesth. Analg. 106, 645-646 (2008). (Pubitemid 351156695)
80. Leshner, A. I. Addiction is a brain disease, and it matters. Science 278, 45-47 (1997). (Pubitemid 27446268)
81. Long, M., Barnes, E., Herfarth, H. & Drossman, D. Narcotic use for inflammatory bowel disease and risk factors during hospitalization. Inflamm. Bowel Dis. 18, 869-876 (2012).
82. Chou, R. et al. Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. J. Pain 10, 113-130 (2009).
83. Chou, R., Ballantyne, J. C., Fanciullo, G. J., Fine, P. G. & Miaskowski, C. Research gaps on use of opioids for chronic noncancer pain: findings from a review of the evidence for an American Pain Society and American Academy of Pain Medicine clinical practice guideline. J. Pain Off. J. Am. Pain Soc. 10, 147-159 (2009).
84. Malekzadeh, M. M. et al. Opium use and risk of mortality from digestive diseases: a prospective cohort study. Am. J. Gastroenterol. 108, 1757-1765 (2013).
85. Roy, S. et al. Opioid drug abuse and modulation of immune function: consequences in the susceptibility to opportunistic infections. J. Neuroimmune Pharmacol. 6, 442-465 (2011).
86. Lichtenstein, G. R. et al. Serious infections and mortality in association with therapies for Crohn's Disease: TREAT Registry. Clin. Gastroenterol. Hepatol. 4, 621-630 (2006).
87. Cook, S. F. et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment. Pharmacol. Ther. 27, 1224-1232 (2008). (Pubitemid 351697276)